ACRIVON THERAPEUTICS INC. - COMMON STOCK

Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference

27 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors

08 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

06 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 Jan 2024 16:00:24 By Nasdaq GlobeNewswire

Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

04 Jan 2024 08:00:01 By Nasdaq GlobeNewswire

Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer

03 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

21 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference

21 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

09 Nov 2023 08:01:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

16 Oct 2023 08:00:01 By Nasdaq GlobeNewswire

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

28 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

19 Sep 2023 16:32:13 By Nasdaq GlobeNewswire

Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon’s AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies

05 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics to Participate in Two Investor Conferences in September

30 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

17 Aug 2023 16:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

11 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Announces the Appointment of Adam Levy, Ph.D., M.B.A., Experienced Biotech Investor Relations and Strategy Executive, to Senior Vice President and Head, Investor Relations and Corporate Affairs

20 Jul 2023 08:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors

22 Jun 2023 16:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics to Present at the Jefferies Healthcare Conference

02 Jun 2023 08:00:00 By Nasdaq GlobeNewswire